TargetMol

Atreleuton

Product Code:
 
TAR-T14343
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T14343-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T14343-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T14343-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Atreleuton (ABT-761) exhibits potent and selective inhibition of leukotriene formation[1][2][3]. Atreleuton (ABT-761) is a selective, reversible, and orally bioavailable 5-Lipoxygenase (5-LO) inhibitor.
CAS:
154355-76-7
Formula:
C16H15FN2O2S
Molecular Weight:
318.37
Purity:
0.98
SMILES:
C[C@H](C#Cc1ccc(Cc2ccc(F)cc2)s1)N(O)C(N)=O

References

1. VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease. VIA Pharmaceuticals, Inc. 2. Reid JJ, et al. ABT-761 (Abbott). Curr Opin Investig Drugs. 2001 Jan;2(1):68-71. 3. Bell RL, et al. ABT-761 attenuates bronchoconstriction and pulmonary inflammation in rodents. J Pharmacol Exp Ther. 1997 Mar;280(3):1366-73.